This Article Full Text Full Text (PDF) Correction (v13,p3433) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van derVliet, H. J.J. Articles by Exley, M. A. Search for Related Content PubMed PubMed Citation Articles by van derVliet, H. J.J. Articles by Exley, M. A.

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Authors' Affiliations: ¹ Cancer Biology Program, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; ² Department of Internal Medicine, Vrije Universiteit Medisch Centrum, Amsterdam, the Netherlands; and ³ Department of Immunology, University of Washington, Seattle, Washington

Requests for reprints: Mark A. Exley, Harvard Institutes of Medicine, 330 Brookline Avenue, Boston, MA 02115. Phone: 617-667-0982; E-mail: mexley{at}bidmc.harvard.edu.

Purpose: High-dose recombinant human interleukin-2 (IL-2) therapy is of clinical benefit in a subset of patients with advanced melanoma and renal cell cancer. Although IL-2 is well known as a T-cell growth factor, its potential in vivo effects on human immunoregulatory cell subsets are largely unexplored.

Experimental Design: Here, we studied the effects of high-dose IL-2 therapy on circulating dendritic cell subsets (DC), CD1d-reactive invariant natural killer T cells (iNKT), and CD4⁺CD25⁺ regulatory-type T cells.

Results: The frequency of both circulating myeloid DC1 and plasmacytoid DC decreased during high-dose IL-2 treatment. Of these, only a significant fraction of myeloid DC expressed CD1d. Although the proportion of Th1-type CD4^– iNKT increased, similarly to DC subsets, the total frequency of iNKT decreased during high-dose IL-2 treatment. In contrast, the frequency of CD4⁺CD25⁺ T cells, including CD4⁺Foxp3⁺ T cells, which have been reported to suppress antitumor immune responses, increased during high-dose IL-2 therapy. However, there was little, if any, change of expression of GITR, CD30, or CTLA-4 on CD4⁺CD25⁺ T cells in response to IL-2. Functionally, patient CD25⁺ T cells at their peak level (immediately after the first cycle of high-dose IL-2) were less suppressive than healthy donor CD25⁺ T cells and mostly failed to Th2 polarize iNKT.

Conclusions: Our data show that there are reciprocal quantitative and qualitative alterations of immunoregulatory cell subsets with opposing functions during treatment with high-dose IL-2, some of which may compromise the establishment of effective antitumor immune responses.

This article has been cited by other articles:

				R. J. Lechleider, P. M. Arlen, K.-Y. Tsang, S. M. Steinberg, J. Yokokawa, V. Cereda, K. Camphausen, J. Schlom, W. L. Dahut, and J. L. Gulley Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant Clin. Cancer Res., August 15, 2008; 14(16): 5284 - 5291. [Abstract] [Full Text] [PDF]

				B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion Blood, August 15, 2008; 112(4): 1175 - 1183. [Abstract] [Full Text] [PDF]

				H. J. J. van der Vliet, R. Wang, S. C. Yue, H. B. Koon, S. P. Balk, and M. A. Exley Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells J. Immunol., June 1, 2008; 180(11): 7287 - 7293. [Abstract] [Full Text] [PDF]

				D. F. McDermott and M. B. Atkins More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793. [Full Text] [PDF]

				J. K. Sandberg and M. Moll Effects of Interleukin-2 Treatment on CD1d-Restricted Natural Killer T Cells Clin. Cancer Res., July 15, 2007; 13(14): 4311 - 4311. [Full Text] [PDF]